MX2023005273A - Composiciones farmaceuticas de un inhibidor de cinasa. - Google Patents
Composiciones farmaceuticas de un inhibidor de cinasa.Info
- Publication number
- MX2023005273A MX2023005273A MX2023005273A MX2023005273A MX2023005273A MX 2023005273 A MX2023005273 A MX 2023005273A MX 2023005273 A MX2023005273 A MX 2023005273A MX 2023005273 A MX2023005273 A MX 2023005273A MX 2023005273 A MX2023005273 A MX 2023005273A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- kinase inhibitor
- relates
- modulating
- disorder
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención hace referencia a con composiciones farmacéuticas del inhibidor c-Met, Compuesto 1. La invención también hace referencia a métodos de tratamiento de una enfermedad, un trastorno o un síndrome mediado al menos parcialmente por la modulación de la actividad in vivo de una proteína cinasa con la composición farmacéutica y a procesos para producir las composiciones farmacéuticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110124P | 2020-11-05 | 2020-11-05 | |
| PCT/US2021/057996 WO2022098828A1 (en) | 2020-11-05 | 2021-11-04 | Pharmaceutical compositions of a kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005273A true MX2023005273A (es) | 2023-05-23 |
Family
ID=78820880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005273A MX2023005273A (es) | 2020-11-05 | 2021-11-04 | Composiciones farmaceuticas de un inhibidor de cinasa. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230398108A1 (es) |
| EP (1) | EP4240333A1 (es) |
| JP (1) | JP2023548855A (es) |
| KR (1) | KR20230104186A (es) |
| CN (1) | CN116406261A (es) |
| AU (1) | AU2021374669A1 (es) |
| CA (1) | CA3196001A1 (es) |
| CL (1) | CL2023001268A1 (es) |
| CO (1) | CO2023005942A2 (es) |
| CR (1) | CR20230223A (es) |
| IL (1) | IL302485A (es) |
| MX (1) | MX2023005273A (es) |
| PE (1) | PE20240223A1 (es) |
| TW (1) | TW202227061A (es) |
| WO (1) | WO2022098828A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117603138A (zh) * | 2018-01-26 | 2024-02-27 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| TW202334090A (zh) * | 2021-11-03 | 2023-09-01 | 美商艾克塞里克斯公司 | 用於治療激酶依賴性病症之化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103221035A (zh) * | 2010-07-16 | 2013-07-24 | 埃克塞里艾克西斯公司 | C-met调节剂药物组合物 |
| EP2981263B1 (en) * | 2013-04-04 | 2022-06-29 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
| WO2016079687A1 (en) * | 2014-11-18 | 2016-05-26 | Lupin Limited | Oral pharmaceutical composition of teriflunomide |
| CN117603138A (zh) | 2018-01-26 | 2024-02-27 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| SG11202105949RA (en) | 2018-12-13 | 2021-07-29 | Exelixis Inc | Crystalline forms and salt forms of a kinase inhibitor |
| WO2020135401A1 (zh) * | 2018-12-24 | 2020-07-02 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物的治疗用途及其固体药物组合物 |
-
2021
- 2021-11-04 CA CA3196001A patent/CA3196001A1/en active Pending
- 2021-11-04 CR CR20230223A patent/CR20230223A/es unknown
- 2021-11-04 PE PE2023001561A patent/PE20240223A1/es unknown
- 2021-11-04 KR KR1020237017606A patent/KR20230104186A/ko unknown
- 2021-11-04 EP EP21819284.7A patent/EP4240333A1/en active Pending
- 2021-11-04 JP JP2023526968A patent/JP2023548855A/ja active Pending
- 2021-11-04 US US18/035,355 patent/US20230398108A1/en active Pending
- 2021-11-04 IL IL302485A patent/IL302485A/en unknown
- 2021-11-04 MX MX2023005273A patent/MX2023005273A/es unknown
- 2021-11-04 CN CN202180074166.6A patent/CN116406261A/zh active Pending
- 2021-11-04 AU AU2021374669A patent/AU2021374669A1/en active Pending
- 2021-11-04 WO PCT/US2021/057996 patent/WO2022098828A1/en active Application Filing
- 2021-11-05 TW TW110141305A patent/TW202227061A/zh unknown
-
2023
- 2023-05-03 CL CL2023001268A patent/CL2023001268A1/es unknown
- 2023-05-09 CO CONC2023/0005942A patent/CO2023005942A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230398108A1 (en) | 2023-12-14 |
| KR20230104186A (ko) | 2023-07-07 |
| CN116406261A (zh) | 2023-07-07 |
| CA3196001A1 (en) | 2022-05-12 |
| CL2023001268A1 (es) | 2023-12-11 |
| AU2021374669A9 (en) | 2024-04-18 |
| IL302485A (en) | 2023-06-01 |
| EP4240333A1 (en) | 2023-09-13 |
| CR20230223A (es) | 2023-07-07 |
| PE20240223A1 (es) | 2024-02-16 |
| AU2021374669A1 (en) | 2023-06-15 |
| TW202227061A (zh) | 2022-07-16 |
| JP2023548855A (ja) | 2023-11-21 |
| WO2022098828A1 (en) | 2022-05-12 |
| CO2023005942A2 (es) | 2023-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005273A (es) | Composiciones farmaceuticas de un inhibidor de cinasa. | |
| MX2021006951A (es) | Formas cristalinas y formas de sal de un inhibidor de cinasa. | |
| EA200001258A1 (ru) | Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| UA103617C2 (ru) | Производные тиенопиридона как активаторы амр-активированной протеинкиназы (амрк) | |
| UA86614C2 (ru) | Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата | |
| BRPI0606690A2 (pt) | composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica | |
| HK1116161A1 (en) | Substituted amide derivatives as protein kinase inhibitors | |
| UA99882C2 (uk) | Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти) | |
| EA200501710A1 (ru) | Замещённые карбоновые кислоты | |
| MX2021014773A (es) | Formas de sales cristalinas de un inhibidor de cinasas. | |
| MX2022001784A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos. | |
| MX2022013647A (es) | Imidazopiridazinas como moduladores de il-17. | |
| MX2021012706A (es) | Inhibidores de dihidroorotato deshidrogenasa. | |
| EP2124990A4 (en) | TUMOR TREATMENT BASED ON ROMIDEPSIN | |
| MX2021015874A (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. | |
| MX2021009521A (es) | Inhibidores de dihidroorotato deshidrogenasa. | |
| MX2021006619A (es) | Inhibidores de la tirosina quinasa, composiciones y sus metodos. | |
| ATE419249T1 (de) | Inhibitoren von mitotischem kinesin | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| MX2022002597A (es) | Métodos de tratamiento de la epilepsia usando los métodos. | |
| MX2022012575A (es) | Compuestos para usarse para tratar la enfermedad de huntington. | |
| MX2022013650A (es) | Imidazopirimidinas como moduladores de il-17. | |
| MX2022014925A (es) | Moduladores de il-17a. | |
| MX2022011550A (es) | Composiciones y métodos para inhibir la expresión de angptl3. |